EyePoint Pharmaceuticals

Press Releases

pSivida Plans Medidur™ EU Marketing Approval Application Based on Single Phase 3 Clinical Trial
Dec 28, 2015
WATERTOWN, Mass. , Dec. 28, 2015 (GLOBE NEWSWIRE) -- pSivida Corp.  (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that it plans to file for EU marketing approval of Medidur™ for chronic non-infectious
pSivida's Medidur™ Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis (p Less Than 0.00000001)
Dec 22, 2015
Statistical Significance in Improvement in Visual Acuity and Reduction in Systemic Therapy  Medidur™, pictured below the pencil, is an injectable micro-insert designed to treat posterior uveitis. Injected into the back of the eye, it provides sustained release of 0.18 mg of a corticosteroid
pSivida Corp. Provides Company Update and Reports First Quarter FY 2016 Results
Nov 05, 2015
WATERTOWN, Mass. , Nov. 05, 2015 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV), (ASX:PVA),  a leader in the development of sustained release, drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its first fiscal quarter ended
pSivida Corp Announces First Quarter FY 2016 Financial Results Release Date and Conference Call Information
Oct 30, 2015
WATERTOWN, Mass. , Oct. 30, 2015 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the first quarter of fiscal year 2016 will be released after
pSivida Announces NDA for Medidur™ Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs
Sep 28, 2015
Top-Line Data from First Trial Expected December 2015 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, announced that the Company now plans to file a New Drug Application
pSivida CEO to Present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015
Sep 14, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton , President and CEO, will present at the Ladenburg Thalmann 2015 Healthcare Conference
pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2015 Results
Sep 09, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its fourth quarter and fiscal year ended June 30, 2015
pSivida CEO Invited to Speak at Surfaces in BioMaterials Foundation's BioInterface 2015 Annual Symposium
Sep 03, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced Dr. Paul Ashton , president and CEO of pSivida Corp. , will speak at the BioInterface 2015 Annual Symposium
pSivida Corp Announces Fourth Quarter and Fiscal Year 2015 Financial Results Release Date and Conference Call Information
Sep 02, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the fourth quarter and fiscal year 2015 will be released after the market
pSivida CEO to Speak at Controlled Release Society Annual Meeting Workshop in Edinburgh, Scotland, This Weekend
Jul 21, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced Dr. Paul Ashton , president and CEO of pSivida Corp. , will speak at a special workshop focusing on ocular
pSivida Announces Positive Top Line Results From Investigator-Sponsored Phase II Study of Medidur™ for Uveitis
Jul 13, 2015
Statistically Significant Reduction in Recurrence of Disease and Statistically Significant Improvement in Visual Acuity WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases,
pSivida Announces Top-Line Results from Investigator-Sponsored Phase II Study of Medidur™ for Uveitis to Be Reported Next Week
Jul 07, 2015
Dr. Glenn J. Jaffe to Present at 33 rd Annual Scientific Meeting of American Society of Retina Specialists WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, announced that
pSivida CEO to Present at ISOPT Clinical Meeting in Berlin in July 2015
Jun 24, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced Dr. Paul Ashton , president and CEO of pSivida Corp. , will present at the International Symposium on Ocular
pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur™ for Posterior Uveitis
May 19, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV); (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced positive safety data from its ongoing assessment of masked safety data from its first Phase III clinical
pSivida Announces Two Tech Evaluation Agreements with Leading Global Pharmaceutical Company
May 12, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in developing sustained release, drug delivery products for treating eye diseases, today announced that it has signed two funded technology evaluation agreements with a leading global pharmaceutical company.
pSivida Corp. Reports Third Quarter FY 2015 Results
May 08, 2015
Clear FDA Regulatory Path for Medidur ™ for Posterior Uveitis NDA Filing Planned in First Half of 2017 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced
pSivida Corp. Announces Third Quarter Fiscal Year 2015 Financial Results Release Date and Conference Call Information
May 01, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year 2015 will be released before the market open
pSivida Corp. Reports ILUVIEN® for DME Approved in Poland
Apr 14, 2015
Marks 17 th European Approval WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the Office for Registration of Medicinal Products , Medical Devices and
pSivida Corp. Completes Targeted Enrollment of Phase III Trial of Medidur™ for Posterior Uveitis
Mar 26, 2015
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the completion of the originally targeted enrollment of 120 patients in its pivotal Phase III clinical trial
pSivida Announces U.S. Shipments of ILUVIEN® for DME to Start February 23
Feb 17, 2015
Live Launch Webinar on March 2 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that initial nationwide shipments of ILUVIEN® for diabetic macular edema
Displaying 101 - 120 of 333
EyePoint Pharmaceuticals